Consequences of the inhibition of Hdm2 expression in human osteosarcoma cells using antisense oligonucleotides

T Geiger1, D Hüsken, J Weiler

  • 1Department of Oncology, Nucleic Acid Sciences, Novartis Pharma Inc, Basel, Switzerland. thomas.geiger@pharma.novartis.com

Anti-Cancer Drug Design
|November 22, 2001
PubMed

Insights

Researchers identified a potent antisense oligonucleotide (ASO), NCH-4401, that effectively inhibits Hdm2 expression in human cancer cells. This inhibition leads to p53 and p21 induction but does not trigger apoptosis, even when combined with chemotherapy agents.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Hdm2 is a key regulator of p53 stability and function.
  • Inhibiting Hdm2 offers a potential therapeutic strategy for cancers with wild-type p53.
  • Antisense oligonucleotides (ASOs) provide a targeted approach to modulate gene expression.

Purpose of the Study:

  • To identify and characterize a potent, sequence-specific antisense oligonucleotide (ASO) targeting Hdm2 mRNA.
  • To investigate the downstream effects of Hdm2 inhibition on p53 pathway activation and apoptosis in human cancer cells.

Main Methods:

  • Synthesis and screening of chimeric 2'-O-methoxyethyl (MoE)-modified ASOs targeting Hdm2 mRNA.
  • Determination of IC50 values for ASO potency and specificity.
  • Assessment of Hdm2 protein levels, p53 and p21 induction, and apoptosis markers (caspase-3 activity, Yopro staining).

Main Results:

  • NCH-4401 demonstrated potent and sequence-specific inhibition of Hdm2 expression in SJSA-1 cells (IC50 = 120 nM).
  • Hdm2 protein inhibition by NCH-4401 led to significant induction of p53 (12.5-fold) and p21 (8-fold).
  • NCH-4401 alone did not induce apoptosis and did not potentiate apoptosis induced by carboplatin or mitomycin C.

Conclusions:

  • NCH-4401 is a potent inhibitor of Hdm2 expression with potential therapeutic applications.
  • Hdm2 inhibition activates the p53 pathway but does not directly induce apoptosis in osteosarcoma cells.
  • Combined Hdm2 inhibition and DNA-damaging chemotherapy does not enhance programmed cell death in this model.